Eli Lilly's GLP-1 Drugs Power Record $65.2B Revenue, Fueling Trillion-Dollar Valuation
Driven by blockbuster sales of its weight-loss and diabetes treatments, Eli Lilly's 2025 revenue surged 45%, with the company forecasting even stronger growth for 2026 as it prepares to launch a pivotal oral therapy.